| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-451
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-075 |
| filingDate |
2001-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_390ea249d8a1a8bc5d85b12dce771072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1051678351e9853a72cff691927f06ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1176de9a6d0333c78f3db171e9c560f |
| publicationDate |
2002-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1186303-A2 |
| titleOfInvention |
Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| abstract |
This invention relates to methods of treating traumatic brain injury (TBI) or hypoxic ornischemic stroke, comprising administering to a patient in need of such treatment an NR2Bnsubtype selective N-methyl-D-aspartate (NMDA) receptor antagonist in combination withneither: (a) a neutrophil inhibitory factor (NIF); (b) a sodium channel antagonist; (c) a nitricnoxide synthase (NOS) inhibitor; (d) a glycine site antagonist; (e) a potassium channel opener;n(f) an AMPA/kainate receptor antagonist; (g) a calcium channel antagonist; (h) a GABA-Anreceptor modulator (e.g., a GABA-A receptor agonist); or (i) an antiinflammatory agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1284141-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1284141-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103230581-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006010966-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2003252499-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-010893-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004006956-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103230581-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1199067-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1199067-A2 |
| priorityDate |
2000-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |